384 results for "Neuroplasticity"
Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder
OpenAlex – July 18, 2025
Summary
Psilocybin, a psychedelic alkaloid, appears to alter the epigenome, potentially explaining its lasting benefits for psychiatric conditions like alcohol use disorder. In 40 patients, a genome-wide association study of DNA methylation revealed changes after a 25mg dose. One CpG site in TLE4 and altered RASGRP4 methylation showed an association with psilocybin treatment. These epigenetic shifts relate to neuroplasticity and immune functions, suggesting a biological basis for reduced drinking behavior and depressive symptoms, crucial for psychology and psychiatry.
Abstract
Abstract The serotonergic hallucinogen psilocybin has shown potential as a treatment for psychiatric conditions like alcohol use disorder (AUD) and...
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence
Zenodo (CERN European Organization for Nuclear Research) – January 26, 2026
Summary
Psilocybin, a potent hallucinogen, offers rapid, sustained antidepressant effects for major depressive disorder. Clinical trials, including randomized controlled trials, show large effect sizes and higher remission rates than conventional treatments, with benefits lasting up to a year. Functional neuroimaging reveals psilocybin's impact on neuroplasticity, reducing amygdala activity and altering the default mode network. While adverse effects are mild, the integration of clinical psychology support is crucial. This neuroscience breakthrough in psychiatry medicine holds significant promise for depressive symptoms.
Abstract
This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analys...
PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS
Journal of medical & health sciences review. – March 11, 2025
Summary
Psilocybin, MDMA, and Lysergic acid diethylamide (LSD) offer sustained relief for depression and PTSD after just a few sessions, a profound shift in Psychiatry. These powerful Hallucinogens, often produced via Chemical synthesis as alkaloids, are revolutionizing Medicine. Psychedelics and Drug Studies reveal their Pharmacology impacts neuroplasticity through serotonergic receptors, moving beyond traditional Psychology. While Mescaline is another related compound, the focus is on these specific agents, whose therapeutic efficacy is rigorously explored despite legal and ethical challenges.
Abstract
Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders inclu...
Reunion Neuroscience raises $103 million
C&EN Global Enterprise – May 20, 2024
Summary
A novel psychedelic drug, RE104, offers significantly shorter treatment times for mental health conditions. Unlike psilocybin therapy, which can last 6-8 hours, RE104 sessions are expected to take half that duration. This biotechnology innovation, developed by Reunion Neuroscience, recently secured $103 million to advance treatments for adjustment disorder and postpartum depression. Acting on the brain's serotonin 2A receptor, RE104 aims to boost neuroplasticity and create new neural pathways, a critical area in neuroscience and cognitive science.
Abstract
Reunion Neuroscience , a start-up focused on mental health, has raised a $103 million series A round, co-led by MPM BioImpact and the Novo Nordisk ...
Supplementary file 1_Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.docx
OPAL (Open@LaTrobe) (La Trobe University) – August 06, 2025
Summary
Veterans struggling with mental illness experienced remarkable improvements following psilocybin retreats. Among 21 participants, depression scores plummeted by 65%, PTSD by 50%, and anxiety by 28%. Electroencephalography revealed brain changes reflecting neuroplasticity, suggesting enhanced emotional regulation and cognitive control. This clinical psychology finding offers a promising path in psychiatry and medicine for mental health, potentially influencing arousal and providing alternatives to typical treatments like Sertraline.
Abstract
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effec...
Supplementary file 2_Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.docx
OPAL (Open@LaTrobe) (La Trobe University) – August 06, 2025
Summary
Veterans with traumatic brain injuries experienced profound mental health improvements following psilocybin retreats. Among 21 participants, clinical depression scores decreased by 65%, PTSD by 50%, and anxiety by 28%. This positions psilocybin as a promising tool in Psychiatry and Clinical Psychology for addressing mental illness. Electroencephalography revealed brain changes suggesting enhanced neuroplasticity and improved neural communication, offering a new frontier in Medicine. These significant psychological benefits, including reduced arousal, underscore psilocybin's potential to foster well-being and alleviate complex mental health challenges.
Abstract
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effec...
Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process
Frontiers in Pharmacology – April 05, 2018
Summary
Ayahuasca might uniquely heal traumatic memories by targeting their core emotional components. Neuroscience suggests its alkaloids, like DMT, activate SIGMAR1 receptors and inhibit monoamine oxidase. This neuropharmacological action facilitates retrieval of repressed traumatic memories, making them labile. During memory consolidation, enhanced neuroplasticity allows the fear response to be reprogrammed. Psychology indicates this could update the memory's significance. This Neuroscience and Neuropharmacology Research proposes Ayahuasca as a groundbreaking pharmacological treatment for PTSD.
Abstract
Ayahuasca ingestion modulates brain activity, neurotransmission, gene expression and epigenetic regulation. N,N-Dimethyltryptamine (DMT, one of the...
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Journal of Psychedelic Studies – September 01, 2019
Summary
Psychedelics, a focus of modern Drug Studies, offer profound benefits beyond treatment, enhancing well-being in healthy individuals. These powerful hallucinogens, including compounds like Mescaline, foster enduring increases in Mindfulness and Prosocial behavior. Psychology reveals they boost Openness to experience, a key Personality trait, and improve Attunement to nature, impacting social psychology. Such experiences facilitate psychotherapeutic gains by modulating neuroplasticity, suggesting deeper biochemical mechanisms at play.
Abstract
We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of menta...
Psilocybin's Emerging Role in Combating Depressive Disorder
Journal of Education Health and Sport – August 08, 2023
Summary
A compelling finding in Mental Health Research Topics: Psilocybin, a naturally synthesized hallucinogen, shows remarkable promise for treating persistent depression and anxiety. Clinical psychology trials reveal that combined with psychotherapy, this psychedelic provides enduring alleviation of symptoms, with improvements largely equivalent to standard antidepressant medicine. Psilocybin influences the default mode network, fostering neuroplasticity and altering cognition. This neuroscience-backed approach in psychiatry could revolutionize medicine, offering new hope for widespread psychological challenges.
Abstract
In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select s...
5mC and 5hmC Detection Highlights How Psychedelics Affect Brain Epigenetic Patterns
Zenodo (CERN European Organization for Nuclear Research) – November 04, 2025
Summary
Psilocybin, a serotonergic compound, rapidly rewires brain biology, revealing profound antidepressant mechanisms. In 3 mice, 1,404 regions of 5-Hydroxymethylcytosine (5hmC) DNA demethylation appeared in the Prefrontal cortex. These Epigenetics changes, critical for glutamatergic neuroplasticity, act as a mediator. This Neuroscience insight into DNA methylation, explored in Psychedelics and Drug Studies, illuminates how biology sustains mood regulation. Findings inform Psychology, hippocampal formation, and forensic toxicology in conditions like Schizophrenia.
Abstract
Background: Psilocybin, a serotonergic psychedelic compound, has demonstrated long-term antidepressant effects, yet its underlying mechanisms remai...
Death risk: Lack of movement: The ignored pandemic of digitalization escalates the COVID-19 crisis
Technoetic Arts – June 01, 2021
Summary
The COVID-19 Pandemic has pushed us past a tipping point in digitalization, escalating physical inactivity and related diseases. This neglect fuels rising Loneliness and Anxiety, threatening global Medicine. Psychology highlights the urgency of integrating physical activity into daily life. Promisingly, combining exercise with microdosing psychedelics, as explored in Drug Studies, alongside Mindfulness and neuroplastic movement practices from Complementary and Alternative Medicine Studies, offers a sustainable path forward. This holistic approach is vital for future well-being, addressing issues beyond Body Image and Dysmorphia Studies.
Abstract
Data analysis from diverse medical fields suggests that we have reached a tipping point in the digitalization dynamic through the ongoing COVID-19 ...
A long trip into the universe: Psychedelics and space travel
Frontiers in Space Technologies – September 15, 2022
Summary
Long-duration space travel poses significant psychological challenges, impacting mood and perception. To bolster astronauts' mental well-being and consciousness during future astrobiology missions, integrating psychedelics is proposed. These plant and fungal molecules, explored in drug studies, could facilitate extended stays in space, akin to how citrus prevented scurvy in 18th-century sea travel. Their ability to modulate biological systems and promote neuroplasticity could be crucial for 21st-century deep space exploration, aiding in processing profound experiences.
Abstract
Prolonged periods in space have potentially deleterious physiological and psychological effects. Ensuring the physical health and mental well-being...
LSD induces increased signalling entropy in rats’ prefrontal cortex
OpenAlex – June 23, 2021
Summary
Psychedelics, like lysergic acid diethylamide (LSD), profoundly reorganize brain signalling by influencing neurotransmitter receptors. In rats, chronic LSD treatment fundamentally rewires gene networks within the prefrontal cortex, making them more complex and increasing signalling entropy—a key feature of neuroplasticity. This molecular entropy, revealed through biochemical analysis, mirrors patterns seen in human neuroimaging, suggesting how these drug studies influence cognition and behavior. This neuroscience insight into biology and synaptic plasticity offers new avenues for psychology and psychiatric treatment.
Abstract
Abstract Psychedelic drugs are gaining attention from the scientific community as potential new compounds for the treatment of psychiatric diseases...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.
Npj mental health research – January 31, 2026
Summary
Magnesium-ibogaine rapidly improves TBI and PTSD in U.S. Special Operations veterans. Narratives from 30 male veterans revealed a profound healing experience. Participants described guided replay of traumatic memories, a sense of altered self and mystical connection, and deep emotional resolution with surges of forgiveness and renewed purpose. They also reported embodied healing, including vivid neural repair, cognitive clarity, and somatic relief. This accelerated, self-directed process suggests powerful mind-body mechanisms driving rapid neuroplastic change, offering new insights into trauma and TBI recovery.
Abstract
Magnesium-ibogaine, a formulation combining ibogaine with pre- and post-treatment magnesium, was recently found to yield rapid clinical improvement...
Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment.
Neuroscience – January 22, 2026
Summary
Fewer than half of patients achieve remission with current Major Depressive Disorder (MDD) treatments, underscoring a critical need for new options. Classic psychedelics are emerging as a promising treatment. These substances interact with brain receptors, enhancing connectivity and promoting neuroplasticity—processes believed to alleviate depression symptoms. Studies indicate classic psychedelics yield favorable, long-term outcomes comparable to traditional therapies, offering a compelling new path for MDD management.
Abstract
Pharmacotherapy for MDD is commonly prescribed to patients, yet fewer than half achieve remission. Moreover, many patients exhibit intolerant respo...
Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.
Annals of medicine and surgery (2012) – January 01, 2026
Summary
Psilocybin offers remarkable promise, providing rapid and sustained symptom relief for major depressive disorder, even in treatment-resistant cases. Evidence from clinical trials conducted between 2014 and 2024 reveals this psychedelic therapy enhances neuroplasticity and brain connectivity. However, its classification as a Schedule I substance significantly impedes further research and broader application. Policy reform is crucial to overcome these regulatory barriers, allowing psilocybin's full potential to be unlocked and integrated into mainstream mental health care.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), p...
The intersection of near-death experiences (NDEs) and traumatic brain injury (TBI): neurobiological, phenomenological, and creative implications.
Frontiers in human neuroscience – January 01, 2025
Summary
Traumatic brain injury (TBI) and near-death experiences (NDEs) can surprisingly catalyze profound human creativity. These extreme altered states profoundly impact neurobiology, reconfiguring brain networks to foster heightened artistic expression and significant personality and spiritual changes. Like psychedelic experience, TBI and NDEs demonstrate the brain's immense neuroplasticity. Understanding these transformations, perhaps through neuropharmacological insights into altered brain function, challenges traditional views of pathology. This unveils new frameworks for human potential, showing how extreme conditions can unlock hidden cognitive reservoirs.
Abstract
Traumatic brain injury (TBI) and near-death experiences (NDEs) represent profound disruptions in brain function, often associated with dramatic cha...
Ketamine in depression and electroconvulsive therapy
Current Opinion in Anaesthesiology – October 01, 2021
Summary
A single intravenous dose of 0.5 mg/kg of ketamine, administered over 40 minutes, delivers a powerful, rapid-onset antidepressant effect. This treatment can alleviate depression and suicidal thoughts within hours, with benefits potentially lasting up to a week. Ketamine and its analog esketamine conclusively demonstrate this swift impact, attributed to improved neuroplasticity in key brain areas. Repeated nasal spray esketamine may prevent depression relapse. Ketamine also enhances seizure quality and could diminish cognitive impairment during electroconvulsive therapy.
Abstract
Purpose of review The antidepressant effect of subanesthetic doses of ketamine was recognized 20 years ago. This review briefly summarizes the curr...
Basic aspects of ketamine therapy for treatment-resistant depression - a review paper
Quality in Sport – July 28, 2024
Summary
Up to 60% of major depression cases resist standard treatments, but ketamine offers a rapid, effective alternative. Its efficacy rivals electroconvulsive therapy, with a significantly faster onset than traditional antidepressants, quickly reducing suicide risk. The FDA approved esketamine for treatment-resistant depression in 2019. Ketamine's therapeutic benefits depend on form and dosage, likely involving brain neuroplasticity for its swift action.
Abstract
Introduction and purpose: Major depressive disorder (MDD) is the most common psychiatric illness, affecting millions of people worldwide. The first...
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin
Journal of Psychopharmacology – November 04, 2020
Summary
Psilocybin, a psychedelic compound from "magic mushrooms," rapidly boosts gene expression linked to neuroplasticity, particularly in the prefrontal cortex. In a study with 20 rats, doses of psilocybin (0.5–20 mg/kg) significantly increased the expression of genes like Cebpb and Sgk1. The prefrontal cortex showed more pronounced changes than the hippocampus, highlighting its crucial role in plasticity. Notably, protein levels for key genes only partially matched transcription data, underscoring the need to evaluate protein translation alongside gene expression in understanding psilocybin's effects.
Abstract
Background: Psilocybin is a serotonergic psychedelic found in “magic mushrooms” with a putative therapeutic potential for treatment-resistant depre...
Ayahuasca potential benefits
European Psychiatry – April 01, 2021
Summary
Ayahuasca shows promise as a therapeutic tool for anxiety, depression, and addiction. Observational studies reveal significant reductions in depressive symptoms, with some participants experiencing decreased alcohol and cocaine use. A review of 100+ studies highlights its ability to promote introspection and emotional processing, akin to psychotherapy. Users often report improvements in mindfulness, comparable to those seen in meditators. The biochemical effects include enhanced neuroplasticity through 5HT2A agonism, suggesting potential benefits for cognition and mental health. Further investigation with larger samples is warranted.
Abstract
Introduction Ayahusca has potential therapeutic beneffits. Objectives Expose the potential beneffits of ayahuasca from neuropharmacology and clinic...
Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org – February 09, 2026
Summary
A novel treatment approach combines 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and Tetrahydrocannabivarin (THCV) to address Treatment-Resistant Depression (TRD) and chronic anxiety. While 5-MeO-DMT provides rapid antidepressant effects, it can induce panic responses in some users. THCV, however, offers anxiolytic benefits without significant psychoactivity at lower doses. This innovative precision vaporization device delivers a specific ratio of both compounds, promoting neuroplasticity while mitigating anxiety, potentially transforming treatment for the 50% of individuals with TRD who do not respond to conventional medications.
Abstract
The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatmen...
Lusaris launches with $60 million
C&EN Global Enterprise – November 07, 2022
Summary
Lusaris Therapeutics has secured $60 million in Series A financing to create innovative treatments for severe neuropsychiatric and neurological conditions. Their lead candidate targets treatment-resistant depression using a formulation of the psychedelic 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) delivered as a dissolvable tablet under the tongue. The compounds, known as serotonergic neuroplastogens, are designed to enhance neural plasticity, potentially revolutionizing approaches to mental health. Additionally, Lusaris has licensed advanced fast-dissolving tablet technology from Catalent for this promising therapy.
Abstract
Lusaris Therapeutics has launched with $60 million in series A financing to develop therapies for severe neuropsychiatric and neurological conditio...
LSD: Mechanisms and relevance to the treatment of depression
Neuroscience & Biobehavioral Reviews – October 10, 2025
Summary
Over 350 million people globally suffer from major depressive disorder (MDD), with around 30% experiencing treatment-resistant depression (TRD). Traditional antidepressants target neurotransmitters like serotonin but often fall short for many. Emerging therapies, particularly psychedelics like LSD, show promise in inducing rapid and lasting antidepressant effects by enhancing neuroplasticity. Ongoing clinical trials are evaluating LSD's efficacy and safety for TRD, potentially revolutionizing psychiatric treatment. This innovative approach could provide hope for patients unresponsive to conventional medications, underscoring the need for further exploration in this area.
Abstract
Major depressive disorder (MDD) is one of the most prevalent psychiatric conditions worldwide, affecting over 350 million people. Standard treatmen...
Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind
Biomedicines – February 25, 2026
Summary
Ayahuasca, a traditional brew containing the powerful hallucinogen DMT, shows significant promise in treating treatment-resistant depression (TRD) and major depressive disorder (MDD). Current evidence highlights four phase II studies with 5-MeO-DMT and one with DMT for TRD, alongside two phase II trials with DMT fumarate for MDD. These compounds enhance neuroplasticity and reorganize brain networks linked to cognition and mood regulation. With growing interest in psychedelics, they not only offer therapeutic potential but also deepen our understanding of mental health and brain function.
Abstract
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics ...
Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies
Pharmaceuticals – February 14, 2026
Summary
Glaucoma, affecting over 70 million people globally, is not just about high eye pressure; it’s a complex neurodegenerative disorder linked to ischemia and chronic inflammation. Retinal ganglion cells suffer from oxidative stress and neuroinflammation, leading to progressive visual pathway disconnection. Current treatments focus on lowering intraocular pressure but overlook neuroprotection. Emerging compounds like ketamine and psilocybin show promise in enhancing neuroplasticity and reducing inflammation, potentially addressing unmet therapeutic needs in glaucoma by promoting neuronal regeneration and improving synaptic health.
Abstract
Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve co...
Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
Psychedelics. – October 14, 2025
Summary
Psychedelics like psilocybin and MDMA show promise in treating stress-related psychiatric disorders, which affect millions globally and often resist conventional treatments. Chronic stress significantly contributes to conditions such as depression and anxiety, impacting public health. These substances can alter consciousness and enhance neuroplasticity, potentially improving emotional processing and serotonin function. By exploring the mechanisms behind these effects, a transformative approach to mental health care could emerge, addressing the persistent challenges faced by individuals suffering from anxiety and depression.
Abstract
Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable...
Simulating Synaptic Pruning and Ketamine-Like Recovery in Depression: Insights from Consolidation Duration and Iterative Regimens on Resilience and Relapse
Zenodo (CERN European Organization for Nuclear Research) – January 14, 2026
Summary
Excessive synaptic pruning during adolescence can significantly weaken neural circuits, contributing to major depressive disorder (MDD). In simulations with 396,000 weights, accuracy plummeted to 32% after removing 95%. A single regrowth cycle restored accuracy to about 97%, while extending consolidation periods improved performance by up to 55 percentage points and minimized relapse. Iterative regrowth cycles reduced residual sparsity below 1%, enhancing stress resilience and outperforming one-time restorations. These findings underscore the importance of tailored, multi-dose treatments for fostering long-term neuroplasticity and stability in MDD.
Abstract
Background: Major depressive disorder (MDD) is increasingly framed as a failure of neuroplasticity. Excessive synaptic pruning in adolescence can l...
The collective lie in ketamine therapy: a call to realign clinical practice with neurobiology
Frontiers in Psychiatry – September 22, 2025
Summary
Ketamine therapy is often misinterpreted as a consciousness-expanding treatment, but its true function lies in promoting neuroplasticity as an NMDA receptor antagonist. With a narrative review of clinical data, it reveals that the acute dissociative experience associated with ketamine-assisted psychotherapy (KAP) is not essential for effective treatment. Instead, lasting mental health improvements stem from neurobiological changes occurring days after administration. Prioritizing subjective experiences over biological processes risks distorting memory and undermining treatment potential, highlighting the need for evidence-based protocols in clinical practice.
Abstract
In recent years, ketamine therapy has become increasingly entangled with psychedelic culture, leading to widespread misinterpretation of its therap...
Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine
Computational and Structural Biotechnology Journal – December 29, 2025
Summary
Antidepressants like ketamine provide rapid relief for major depressive disorder (MDD), acting through glutamatergic pathways and enhancing brain-derived neurotrophic factor (BDNF) levels, promoting neuroplasticity. A meta-analysis of 500 studies revealed that targeting key genes such as GSK3B and opioid receptor mu 1 (OPRM1) could improve treatment outcomes. Additionally, the nuclear factor kappa B (NFKB) was identified as a central regulator linking inflammation and synaptic plasticity. These findings suggest that focusing on these targets may enhance therapeutic strategies for MDD.
Abstract
Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventi...
MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions
Psychedelics. – October 14, 2025
Summary
MDMA, known for its therapeutic potential, has shown remarkable effects in treating resistant posttraumatic stress disorder (PTSD), with clinical trials indicating substantial improvements. In studies involving 100+ participants, MDMA-assisted psychotherapy led to significant reductions in PTSD symptoms. Additionally, large epidemiological studies reveal that MDMA users report 30% lower rates of depression and reduced suicidal thoughts. Animal studies suggest MDMA enhances stress resilience and neuroplasticity. Future efforts aim to refine dosing protocols and safety monitoring for broader applications in mental health treatment.
Abstract
MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increas...
MDMA enhances prefrontal plasticity and representational drift during fear extinction
OpenAlex – March 08, 2026
Summary
MDMA significantly enhances fear extinction by promoting structural and functional neuroplasticity in the brain. In a study involving mice, MDMA increased spine density in the medial prefrontal cortex by 30%, indicating heightened synaptic connections. Additionally, the infralimbic cortex showed improved correlation with reduced freezing behavior during extinction tasks. Over time, neural representations in MDMA-treated mice shifted more rapidly, particularly among neurons that suppressed activity in response to cues. These findings suggest MDMA's potential as a therapeutic agent for improving cognitive processes related to fear and anxiety.
Abstract
Abstract Fear extinction requires dynamic updating of cortical representations, yet the neural mechanisms underlying successful extinction remain p...
Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration
Acta Neuropsychiatrica – February 13, 2026
Summary
Ibogaine shows promise as a potential treatment for neuropsychiatric conditions, including substance use disorder and multiple sclerosis. Observational data suggest that a single dose can lead to symptom relief, with evidence indicating that ibogaine enhances myelination markers after opioid use. White matter pathology is prevalent in conditions like multiple sclerosis, often linked to decreased myelination and metabolic dysregulation. By interacting with various neurotransmitter receptors, ibogaine may reduce excitotoxicity and promote neuroplasticity, offering a compelling rationale for its exploration in central nervous system therapies.
Abstract
Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ...
Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex
OpenAlex – December 18, 2025
Summary
Ibogaine has the potential to rejuvenate neuroplasticity in the adult visual cortex, akin to juvenile levels. In a study with adult mice (n=40), ibogaine treatment (40 mg/kg) combined with four days of monocular deprivation significantly reduced visual acuity and dendritic spine density in the deprived eye. Notably, ibogaine diminished perineuronal nets and parvalbumin-positive interneurons, which typically inhibit plasticity. These findings suggest that ibogaine may facilitate therapeutic effects by re-establishing adaptability in the visual system, challenging traditional views on adult neural rigidity.
Abstract
Abstract Background: Psychedelics have emerged as powerful modulators of neural plasticity, yet whether the atypical psychedelic ibogaine can enhan...
Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.
Molecular neurobiology – June 04, 2025
Summary
Psychedelics like psilocybin and LSD show remarkable potential in treating brain disorders through multiple healing mechanisms. These compounds reduce inflammation and oxidative stress while promoting brain plasticity, offering relief for both psychiatric and neurologic conditions. Early results suggest faster recovery and longer-lasting benefits compared to traditional medications.
Abstract
Neurological and psychiatric disorders are considered one of the major problems of today's societies and cause many individual and social problems....
Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists.
British journal of pharmacology – May 23, 2025
Summary
Breakthrough research reveals that psychedelics like LSD work through serotonin receptors to create their mind-altering effects. Scientists discovered a new class of compounds that target the same brain pathways but don't cause hallucinations, potentially offering antidepressant benefits without the intense psychedelic experience. This finding could revolutionize mental health treatment by harnessing therapeutic effects while minimizing disorienting side effects.
Abstract
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture ...
[Treatment with psychedelics : potential benefits in Parkinson's disease].
Revue medicale suisse – April 23, 2025
Summary
Emerging research reveals that psychedelics may offer new hope for Parkinson's disease patients beyond traditional treatments. These compounds show potential in addressing both motor and non-motor symptoms while possibly protecting brain cells. They stimulate new neural connections, boost protective brain chemicals, and reduce inflammation. Early evidence suggests they could help manage depression and anxiety common in Parkinson's, while their brain-enhancing properties may slow disease progression.
Abstract
Psychedelics, such as psilocybin and lysergic acid diethylamide, modulate neuroplasticity and brain connectivity via 5-HT2A receptors. Their effica...
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Psychopharmacology – April 11, 2025
Summary
A naturally-occurring neurotransmitter in our bodies, DMT has profound effects on brain connectivity. When present, it enhances global neural networks and alters consciousness by binding to specific receptors. Both endogenous and exogenous DMT influence cognition by increasing brain signal complexity and strengthening connections between key regions. This psychedelic compound's unique properties suggest it plays a vital role in consciousness.
Abstract
N, N-Dimethyltryptamine (DMT), a potent serotonergic psychedelic, bridges ancient wisdom and modern science. The mechanisms underlying its powerful...
Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology
OpenAlex – February 06, 2025
Summary
A compelling Neuroscience finding: the hallucinogen psilocybin, a psychedelic, shows promise for repetitive mild head injury. In adult female rats, Medicine observed psilocybin reduced brain swelling (relevant to Neuroradiology), restored vascular function, and lessened harmful tau buildup. Implications exist for Physical medicine and rehabilitation, addressing cognitive and behavioral deficits in Psychology. Psilocybin's neurotransmitter receptor influence on behavior is vital for Psychedelics and Drug Studies, informing broader receptor research like Nicotinic Acetylcholine Receptors Study.
Abstract
Abstract Repetitive mild head injuries incurred while playing organized sports, during car accidents and falls, or in active military service are a...
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.
Current pain and headache reports – January 07, 2025
Summary
Groundbreaking research reveals psychedelics like psilocybin, LSD, and ketamine show remarkable promise in treating chronic pain conditions. These compounds provide powerful analgesic effects while addressing both physical and emotional aspects of pain. Studies demonstrate significant relief for patients with cluster headaches, neuropathic pain, and phantom limb pain through combined psychotherapy and psychedelic treatment.
Abstract
Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on...
Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design
Journal of Eating Disorders – December 27, 2024
Summary
Standard psychological interventions fail one-third of individuals with eating disorders, affecting 1-3% of the population. However, psilocybin-assisted psychotherapy, guided by a psychotherapist, shows promise for these severe mental health conditions like anorexia nervosa and bulimia nervosa. To advance clinical psychology, understanding how this hallucinogen impacts cognition and behavior is crucial. Neuroimaging and other psychedelics and drug studies are vital for conceptualizing the neurobiological mechanisms, informing future psychiatry and psychological intervention development.
Abstract
Eating disorders (EDs) are a group of debilitating mental illnesses characterized by maladaptive eating behaviors and severe cognitive-emotional dy...
Plant-derived compounds and neurodegenerative diseases: Different mechanisms of action with therapeutic potential.
Neuroscience – February 06, 2025
Summary
Nature's compounds offer promising solutions for brain health. Three plant-derived substances - Quercetin (found in fruits), Cannabidiol (from cannabis), and N,N-dimethyltryptamine (from various plants) - show remarkable potential in fighting neurodegenerative diseases. Each works uniquely: Quercetin as an antioxidant, Cannabidiol reduces inflammation, and DMT promotes brain plasticity. Together, they represent a powerful arsenal against neurological decline.
Abstract
Neurodegenerative diseases are a group of disorders characterized by progressive degeneration of discrete groups of neurons causing severe disabili...
CURRENT STATE OF PSILOCYBIN-ASSISTED THERAPY IN MOOD DISORDERS
Psychiatria Danubina – July 17, 2024
Summary
Psilocybin-assisted therapy presents a compelling new direction for treating mood disorders in Psychiatry. A review of eight clinical trials demonstrates significant, immediate, and sustained improvements in depressive and anxious mood. Five trials focused on general depression, while three addressed patients with life-threatening conditions. This emerging medicine, often guided by a Psychotherapist, is safe and feasible, advancing clinical psychology. One comparison showed similar efficacy to standard drug treatments, highlighting psychedelics' potential.
Abstract
Psychedelics are currently undergoing a scientific renaissance, with modern studies investigating therapeutic efficacy of psychedelic-assisted ther...
Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases.
Pharmacological reports : PR – December 01, 2024
Summary
Psilocybin shows remarkable potential in treating depression by triggering a cascade of brain chemistry changes. The compound works by activating 5-HT2A receptors in the brain, which increases glutamate release. This boost in glutamate leads to higher GABA activity, creating a balanced brain state that helps alleviate depressive symptoms and promotes neural adaptability.
Abstract
In recent decades, psilocybin has gained attention as a potential drug for several mental disorders. Clinical and preclinical studies have provided...
Comparing psilocybin to metformin as neuroprotective agents against Parkinson's dementia: A systematic review of evidence and efficacy.
Progress in neuro-psychopharmacology & biological psychiatry – January 10, 2025
Summary
Both metformin and psilocybin show promising potential in protecting brain cells from Parkinson's disease damage. While metformin works by reducing cellular stress and preventing protein buildup, psilocybin promotes brain repair through serotonin pathway activation. This groundbreaking comparison reveals both compounds could offer prophylactic treatment options for neurodegenerative disease prevention.
Abstract
Treatment of Parkinson's disease (PD) has remained largely unchanged and focuses primarily on symptomatic relief through activation of dopaminergic...
CCNP Innovations in Neuropsychopharmacology Award
Journal of Psychiatry and Neuroscience – September 19, 2024
Summary
Psychedelics are profoundly reshaping mental health treatment, offering a novel psychiatric framework. These substances uniquely activate serotonin receptors and influence specific neural circuits, fostering transformative cognitive and spiritual experiences. A Neuropsychopharmacology review elucidates the complex mechanisms of two principal psychedelics, psilocybin and LSD, impacting brain plasticity. This deep Neuroscience and Psychology understanding is vital for future pharmaceutical studies and practices, addressing diverse mental health disorders. Such insights could even extend to conditions like Attention Deficit Hyperactivity Disorder, integrating brain, mind, and spirituality.
Abstract
For 3000 years, psychedelics have been used in religious contexts to enhance spiritual thinking, well-being, and a sense of community. In the last ...
Psychedelics and schizophrenia: a double-edged sword.
Molecular psychiatry – February 01, 2025
Summary
While historically feared as triggers for psychosis, psychedelics may actually help treat certain schizophrenia symptoms. New research reveals these compounds affect brain systems opposite to schizophrenia's effects, particularly for social cognition and negative symptoms. Low doses could benefit chronic patients with predominant negative symptoms, though careful dosing is essential to avoid worsening positive symptoms.
Abstract
Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experim...
Co-administration of midazolam and psilocybin: differential effects on subjective quality versus memory of the psychedelic experience.
Translational psychiatry – September 12, 2024
Summary
Memories of psychedelic experiences may be key to their therapeutic benefits. When researchers combined psilocybin with midazolam (a memory-affecting medication), participants still had meaningful psychedelic experiences but remembered less of them. The weaker their memories, the less insight and well-being they reported afterward, suggesting that retaining the experience matters for positive outcomes.
Abstract
Aspects of the acute experience induced by the serotonergic psychedelic psilocybin predict symptomatic relief in multiple psychiatric disorders and...